Nuvo Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Nuvo Pharmaceuticals's estimated annual revenue is currently $19.9M per year.
- Nuvo Pharmaceuticals received $6.0M in venture funding in August 2017.
- Nuvo Pharmaceuticals's estimated revenue per employee is $201,000
- Nuvo Pharmaceuticals's total funding is $9.1M.
Employee Data
- Nuvo Pharmaceuticals has 99 Employees.
- Nuvo Pharmaceuticals grew their employee count by -4% last year.
Nuvo Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $18.5M | 92 | -1% | N/A | N/A |
#2 | $14.3M | 71 | 6% | N/A | N/A |
#3 | $36M | 179 | 8% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $17.9M | 93 | 3% | $192.2M | N/A |
#6 | $64.9M | 323 | 4% | N/A | N/A |
#7 | $0.5M | 5 | -55% | N/A | N/A |
#8 | $6.8M | 34 | -41% | N/A | N/A |
#9 | $19.5M | 97 | 23% | N/A | N/A |
#10 | $2.5M | 25 | 19% | N/A | N/A |
What Is Nuvo Pharmaceuticals?
Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA licensed GMP facility in Varennes, Québec.
keywords:N/A
$9.1M
Total Funding
99
Number of Employees
$19.9M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nuvo Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Executive Chairman | Reveal Email/Phone |
Nuvo Pharmaceuticals News
Nuvo Pharmaceuticals Inc. - Miravo Healthcare to Present at Bloom Burton & Co. Healthcare Investor Conference. Link copied. 04/20/2022 | 07:03am...
Mississauga, Ontario, Canada - April 19, 2022 - Nuvo Pharmaceuticals® Inc. ... Healthcare Investor Conference. Bloom Burton & Co. Healthcare...
Nuvo Pharmaceuticals Inc. (MRVFF) CEO Jesse Ledger on Q4 2021 Results - Earnings Call Transcript. Mar. 28, 2022 2:38 PM ETNuvo Pharmaceuticals Inc. (MRVFF).
- Q2 2021 Adjusted Total Revenue - $19.9 million -- Q2 2021 Adjusted EBITDA - $7.4 million -- Blexten Canadian Prescriptions Increased 26% Year-Over-Year -- Cambia Canadian Prescriptions Increased 17% Year-Over-Year - Miravo to Host Conference Call/Audio Webcast August 9th at 11:00 a.m. ET M ...
MISSISSAUGA, ON, July 26, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release ...
Other Companies in Mississauga
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $26.7M | 99 | 1% | N/A |
#2 | $21M | 100 | 25% | N/A |
#3 | $21.2M | 101 | 3% | N/A |
#4 | $24.7M | 101 | 53% | N/A |
#5 | $27.5M | 102 | 9% | N/A |
Nuvo Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-08-25 | $6.0M | Undisclosed | Royal Bank of Canada (RBC) | Article |
Nuvo Pharmaceuticals Executives
| Name | Title |
|---|---|
| Mary-Jane Burkett | VP/CFO |
| Jesse Ledger | President/CEO |
| Nicole Rusaw | Interim Chief Financial Officer |
| Bernard Chiasson | Chief Scientific Officer |
| Cally Lunetta | VP Manufacturing |
| Tina Loucaides | VP Secretary & General Counsel |
| Mary-Jane Burkett | VP/CFO |
| Jesse Ledger | President/CEO |